AUSTIN, Texas / May 01, 2024 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that it will release results for its first quarter ended March 31, 2024, after the market close on May 9, 2024. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4:30 p.m. ET).
Earnings Conference Call Information:
Event: | Natera’s First Quarter 2024 Financial Results |
Date: | Thursday, May 9, 2024 |
Time: | 1:30 p.m. PT (4:30 p.m. ET) |
Live Dial-In: | 1 (888) 770-7321 (Domestic) |
| 1 (929) 201-7107 (International) |
Conference ID: | 7684785 |
Webcast: | |
A webcast replay will be available at investor.natera.com. | |
About Natera
Natera™ is a global leader in cell-free DNA and genetic testing, dedicated to oncology, women’s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard-of-care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera’s tests are supported by more than 200 peer-reviewed publications that demonstrate excellent performance. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas, and San Carlos, California. For more information, visit www.natera.com.
| Last Trade: | US$119.95 |
| Daily Change: | -0.55 -0.46 |
| Daily Volume: | 710,724 |
| Market Cap: | US$14.840B |
October 22, 2024 September 16, 2024 September 14, 2024 September 08, 2024 August 08, 2024 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
